PCPT Publications

The following citations are of reports that have been published in the scientific literature concerning the Prostate Cancer Prevention Trial (PCPT). The citations are listed in reverse chronological order.

2007 Publications

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial

• Authors: YC Cohen, KS Liu, NL Heyden, AC Carides, KM Anderson, AG Daifotis, PH Gann
• Journal: Journal of the National Cancer Institute 99(18):1366-1374. (2007).

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial

• Authors: SM Lucia, JI Epstein, PJ Goodman, AK Darke, VE Reuter, F Civantos, CM Tangen, HL Parnes, SM Lippman, FG LaRosa, MW Kattan, ED Crawford, LG Ford, CA Coltman Jr., IM Thompson
• Journal: Journal of the National Cancer Institute 99(18): 1375-1383. (2007).

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial

• Authors: IM Thompson, D Pauler Ankerst, C Chi, PJ Goodman, CM Tangen, SM Lippman, MS Lucia, HL Parnes, CA Coltman, Jr.
• Journal: Journal of Clinical Oncology 25(21):3076-3081. (2007).

Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial

• Authors: CM Moinpour, AK Darke, GW Donaldson, IM Thompson, C Langley, DP Ankerst, DL Patrick, JE Ware, PA Ganz, SA Shumaker, SM Lippman, CA Coltman, Jr.
• Journal: Journal of the National Cancer Institute 99(13):1025-1035. (2007).

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial

• Authors: AR Kristal, KB Arnold, JM Schenk, ML Neuhouser, N Weiss, P Goodman, CM Antvelink, DF Penson, IM Thompson
• Journal: Journal of Urology 177(4):1395-1400. (2007).

Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial

• Authors: CM Moinpour, AK Darke, GW Donaldson, IM Thompson, C Langley, DP Ankerst, DL Patrick, JE Ware, PA Ganz, SA Shumaker, SM Lippman, CA Coltman, Jr.
• Journal: Journal of the National Cancer Institute 99 (13): 1025-1035. (2007).

2006 Publications

The prostate cancer prevention trial: design, biases and interpretation of study results

• Authors: PJ Goodman, IM Thompson, CM Tangen, JJ Crowley, LG Ford, CA Coltman, Jr.
• Journal: Journal of Urology 175 (6): 2234-2242. (2006).

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer

• Authors: IM Thompson, C Chi, DP Ankerst, PJ Goodman, CM Tangen, SM Lippman, MS Lucia, HL Parnes, CA Coltman, Jr.
• Journal: Journal of the National Cancer Institute 98(16):1128-1133. (2006).

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

• Authors: IM Thompson, DP Ankerst, C Chi, PJ Goodman, CM Tangen, MS Lucia, Z Feng, HL Parnes, CA Coltman, Jr.
• Journal: Journal of the National Cancer Institute 98(8):529-534. (2006).

2005 Publications

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

• Authors: RD Etzioni, N Howlader, PA Shaw, DP Ankerst, DF Penson, PJ Goodman, IM Thompson
• Journal: Journal of Urology 174(3):877-881. (2005).

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

• Authors: IM Thompson, DP Ankerst, C Chi, MS Lucia, PJ Goodman, JJ Crowley, HL Parnes, CA Coltman, Jr.
• Journal: Journal of the American Medical Association 294(1):66-70. (2005).

Estimated impact of the prostate cancer prevention trial on population mortality

• Authors: JM Unger; IM Thompson; M LeBlanc; JJ Crowley; PJ Goodman; LG Ford; CA Coltman, Jr.
• Journal: Cancer 103(7):1375-1380. (2005).

Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT)

• Authors: MS Lucia; A Darke; P Goodman; C Tangen; CA Coltman; IM Thompson.
• Journal: Journal of Urology 173(4):451 (#1664). (2005).

Prostate specific antigen (PSA) as a predictor of adverse pathological features at prostatectomy in the Prostate Cancer Prevention Trial (PCPT)

• Authors: MS Lucia; P Goodman; C Tangen; CA Coltman; IM Thompson.
• Journal: Journal of Urology 173(4):143 (#525). (2005).

The performance characteristics of prostate-specific antigen

• Authors: IM Thompson; DP Ankerst; C Chi; P Goodman; C Tangen; CA Coltman, Jr.
• Journal: Journal of Urology 173(4):143 (#526). (2005).

2004 Publications

Implementation of the prostate cancer prevention trial (PCPT)

• Authors: PJ Goodman; CM Tangen; JJ Crowley; SM Carlin; A Ryan; CA Coltman, Jr.; LG Ford; IM Thompson.
• Journal: Controlled Clinical Trials 2:203-222. (2004).

Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter

• Authors: IM Thompson; DK Pauler; PJ Goodman; CM Tangen; MS Lucia; HL Parnes; LM Minasian; LG Ford; SM LIppman; ED Crawford; JJ Crowley; CA Coltman Jr.
• Journal: New England Journal of Medicine 350(22):2239-2246. (2004).

Prostate cancer chemoprevention: an overview of United States trials

• Authors: A Barqawi; IM Thompson; ED Crawford.
• Journal: Journal of Urology 171:S5-S9. (2004).

The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies

• Authors: JM Unger; M LeBlanc; IM Thompson; CA Coltman, Jr.
• Journal: Urologic Oncology: Seminars and Original Investigations 22:362-368. (2004).

2003 Publications

The influence of finasteride on the development of prostate cancer

• Authors: IM Thompson; PJ Goodman; CM Tangen; MS Lucia; GJ Miller; LG Ford; MM Lieber; RD Cespedes; JN Atkins; SM Lippman; SM Carlin; A Ryan; CM Szczepanek; JJ Crowley; CA Coltman, Jr.
• Journal: New England Journal of Medicine 349:215-224. (2003).

The prostate cancer prevention trial: design, status, and promise

• Authors: IM Thompson; C Tangen; P Goodman.
• Journal: World Journal of Urology 21:28-30. (2003).

2002 Publications

Biomarker-based methods for determining noncompliance in a prevention trial.

• Authors: DK Pauler, KB Gower, PJ Goodman, JJ Crowley, IM Thompson.
• Journal: Controlled Clinical Trials 23:675-685. (2002).

Energy from fat is associated with obesity in US men: results from the prostate cancer prevention trial.

• Authors: J Satia-Abouta, RE Patterson, RN Schiller, AR Kristal.
• Journal: Preventive Medicine 34:493-501. (2002).

2001 Publications

The prostate cancer prevention trial: current status and lessons learned.

• Authors: IM Thompson, M Kouril, EA Klein, CA Coltman, A Ryan, P Goodman.
• Journal: Urology 57(Suppl.4A):230-234. (2001).

Promoting adherence to the prostate cancer prevention trial end of study biopsy requirement. (Abstract not available online)

• Authors: AM Ryan, P Goodman, S Hill, C Moinpour.
• Journal: Controlled Clinical Trials 22(2S):88S(#P71). (2001).

Dietary supplement use in the prostate cancer prevention trial: implications for prevention trials.

• Authors: ML Neuhouser, AR Kristal, RE Patterson, PJ Goodman, IM Thompson.
• Journal: Nutrition and Cancer 39(1):12-18. (2001).

2000 Publications

Letter to the Editor: RE: RE: Chemoprevention of urological cancer.

• Authors: IM Thompson, CA Coltman.
• Journal: Journal of Urology 164(4):1321-1322. (2000).

Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors.

• Authors: CM Moinpour, L Lovato, IM Thompson, JE Ware, PA Ganz, DL Patrick, SA Shumaker, GW Donaldson, A Ryan, CA Coltman.
• Journal: Journal of Clinical Oncology 18(9):1942-1953. (2000).

Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. (Abstract not available online)

• Authors: TDK Chung, II Park, L Ignacio, R Catchatourian, MA Kopnick, E Davison, G Conrad, AM Awan, ED Crawford, S Vijayakumar.
• Journal: International Journal of Cancer 90:302-304. (2000).

Minority recruitment in the prostate cancer prevention trial. (Abstract not available online)

• Authors: CM Moinpour, JO Atkinson, SM Thomas, S Millon-Underwood, C Harvey, J Parzuchowski, LC Lovato, AM Ryan, S Hill, E DeAntoni, ER Gritz, IM Thompson, Jr, CA Coltman, Jr.
• Journal: Annals of Epidemiology 10(S8):S85-S91. (2000).

1999 Publications

Letters to the Editor: The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen level.

• Author: CA Coltman.
• Journal: British Journal of Cancer 81(1):184-185. (1999).

Validity of short food frequency questionnaires used in cancer chemoprevention trials: results from the prostate cancer prevention trial. (Abstract not available online)

• Authors: ML Neuhouser, AR Kristal, D McLerran, RE Patterson, J Atkinson.
• Journal: Cancer Epidemiology Biomarkers & Prevention 8:721-725. (1999).

Prostate cancer prevention trial (PCPT) update.

• Authors: CA Coltman Jr, IM Thompson Jr, P Feigl.
• Journal: European Urology 35:544-547. (1999).

1998 Publications

Army and Air Force leadership in the prostate cancer prevention trial.

• Authors: J Allerton, T Seay, S Optenberg, CA Coltman Jr, B Higgins, I Thompson, L Lovato.
• Journal: Urology 51(Suppl.4A):64-66. (1998).

1997 Publications

Chemoprevention of prostate cancer: The prostate cancer prevention trial.

• Authors: IM Thompson, CA Coltman Jr, J Crowley.
• Journal: The Prostate 33:217-221. (1997).

Data operations management with clinical datafax: The prostate cancer prevention trial (PCPT) experience. (Abstract not available online)

• Authors: AM Ryan, L Emel, P Goodman.
• Journal: Controlled Clinical Trials 18(S3)(#P74):156S. (1997).

Utility of the enrollment period in the prostate cancer prevention trial (PCPT). (Abstract not available online)

• Authors: PJ Goodman, L Lovato, A Ryan, J Crowley, C Moinpour, I Thompson.
• Journal: Controlled Clinical Trials 18(S3)(#19):52S. (1997).

1996 Publications

Prostate cancer prevention trial. (Abstract not available online)

• Author: BH Zoltick.
• Presented at the AUAA Annual Assembly-Orlando Florida May 4-7 :. (1996).

Screening for prostate cancer: Opportunities for prevention. (Abstract not available online)

• Authors: IM Thompson, CA Coltman Jr.
• Journal: Seminars in Urologic Oncology 14(2)(Suppl.2):4-11. (1996).

The prostate cancer prevention trial: Efforts to increase the recruitment of minority participants. (Abstract not available online)

• Author: CM Moinpour.
• Poster for Conf on the Recruit and Retention of Min Parts in CCR 1/26-27/96 :. (1996).

1995 Publications

Chemoprevention of prostate cancer with finasteride: An Intergroup trial. (Abstract not available online)

• Authors: CA Coltman Jr, P Feigl, IM Thompson.
• Journal: Cancer Investigation 13(Suppl.1):43(#36). (1995).

Chemoprevention of prostate cancer with finasteride.

• Authors: I Thompson, P Feigl, C Coltman.
• Journal: Important Advances in Oncology, JB Lippincott Co :57-76. (1995).

Chemoprevention of prostate cancer.

• Authors: IM Thompson, CA Coltman, OW Brawley, A Ryan.
• Journal: Seminars in Urology 13(2):122-129. (1995).

Design of the prostate cancer prevention trial (PCPT).

• Authors: P Feigl, B Blumenstein, I Thompson, J Crowley, M Wolf, BS Kramer, CA Coltman Jr, OW Brawley, LG Ford.
• Journal: Controlled Clinical Trials 16:150-163. (1995).

1994 Publications

Chemoprevention of prostate cancer with finasteride, an Intergroup trial. (Abstract not available online)

• Authors: CA Coltman Jr, J Unger, IM Thompson.
• Journal: Annals of Oncology [Corrigendum6(6)621-1995]5(Suppl.8):65(#P324). (1994).

Prostate cancer prevention: Risk reduction through life-style, diet, and chemoprevention.

• Authors: KE Greco, L Kulawiak.
• Journal: Oncology Nursing Forum 21(9):1504-1511. (1994).

The prostate cancer prevention trial. A low-risk, high-accrual study. (Abstract not available online)

• Author: J O'Connor.
• Journal: Oncology Issues 9(5):20-24. (1994).